Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
about
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of TuberculosisPartnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
P2860
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
@en
type
label
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
@en
prefLabel
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
@en
P2860
P356
P1476
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
@en
P2093
Efthymios Manolis
Marco Cavaleri
P2860
P356
10.1093/CID/CIV484
P407
P478
61 Suppl 1
P577
2015-08-01T00:00:00Z